Accuracy of Cardiac Wearables Devices to Detect Atrial Fibrillation

Status Completed

Clinical Trial Summary

Atrial fibrillation (AF) is the most common cardiac arrhythmia. This study is to assess the heart rhythm device accuracy of five cardiac wearable devices (Apple Watch, Kardia Mobile/Kardia Mobile 6L, Fitbit Sense, Samsung Galaxy Watch 3 and Withings Scanwatch, Withings SA, Model Number: HWA09) and its detection algorithms in identifying AF compared to a nearly simultaneously acquired physician-interpreted 12-lead ECG in a real world cohort of patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04809922
Study type	Observational
Source	University Hospital, Basel, Switzerland
Contact
Status	Completed
Phase
Start date	April 6, 2021
Completion date	February 28, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02630914` - Medical and Surgical Hybrid Treatment of Atrial Fibrillation.	N/A
Completed	`NCT05410379` - Antral Lesions Characterization of a New Cryoballoon Ablation System in Terms of Local Impedance Drop
Enrolling by invitation	`NCT05407415` - KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial Fibrillation	N/A
Completed	`NCT04025710` - Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)	N/A
Completed	`NCT01119274` - EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon	Phase 4
Recruiting	`NCT03428048` - Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.
Recruiting	`NCT04298723` - Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.	N/A
Completed	`NCT04218266` - Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.	Phase 2
Active, not recruiting	`NCT03732794` - AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment	N/A
Active, not recruiting	`NCT04755283` - Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation	Phase 2
Completed	`NCT04095559` - Characterization of Left Atrial Substrate by Comparison of Bipolar Voltage Maps With Standard Focal 4.5 mm Tip Electrode, 1 mm Ring Electrode, and Microelectrode Catheters Using InTEllaMap Orion and IntellaNav MIFI O
Recruiting	`NCT05712200` - Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)	Phase 3
Recruiting	`NCT05955365` - Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation	Phase 4
Recruiting	`NCT05294445` - From the Emergency Department Directly to Ablation of Atrial Fibrillation Study	N/A
Completed	`NCT02513316` - Clinical Relevance of Microbleeds In Stroke	N/A